KEY PRODUCTS
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
01 1Seqens
01 1MIDAZOLAM
01 1France
01 1Active
01 1Complete
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-05
Pay. Date : 2013-05-22
DMF Number : 12553
Submission : 1997-06-18
Status : Active
Type : II
20
Wavelength Enterprises Ltd, based in France, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
One of their notable products is MIDAZOLAM, with a corresponding US DMF Number 12553.
Remarkably, this DMF maintains an Active status since its submission on June 18, 1997, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 05, 2015, and payment made on May 22, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II
